Many professional liability (malpractice) policies may not cover peptide therapy, so physicians, nurse practitioners, and physician assistants should get written confirmation of coverage before they prescribe a single peptide.
Peptide therapy is one of the fastest-growing services in regenerative, longevity, and wellness medicine. It is also one of the least clearly insured. Underwriters price risk around FDA-approved drugs and accepted standards of care, and most peptides fit neither.
Why peptides create a malpractice coverage gap
Most clinical peptides, including BPC-157, TB-500, GHK-Cu, and CJC1295, are not FDA-approved for any use. They reach patients through compounding pharmacies or research-use-only grey markets, and the rules are still changing. In July 2026, an FDA advisory committee recommended six peptides for the compounding bulks list, but its votes are advisory, and until the FDA completes rulemaking, compounding them is not clearly permitted. Some states have already taken enforcement action.
That uncertainty flows straight into insurance. A committee vote is not FDA approval, and an insurer that wrote your policy before peptides were common may read its exclusions strictly.
Where malpractice policies commonly fall short
- Unapproved or compounded drugs. CM&F Group warns that many policies exclude claims from unapproved drugs, off-label use of non-approved substances, and compounded products.
- Research-labeled product. Prescribing peptides sold for research use only is not lawful for patients and is a common route to a denied claim and a board complaint.
- Product liability and marketing. SeaPort Insurance notes that sterility or labeling failures, and claims such as accelerated tendon regeneration, can fall outside a standard malpractice form.
- Licensing board defense. Defense costs for a board investigation may be limited or excluded.
- Scope of practice. Prescribing outside your legal scope is, in CM&F’s words, a violation that no policy protects against. Nurse practitioners and physician assistants should confirm how their collaborative or supervisory agreements affect coverage.
Many of these sources are brokers and agencies, so treat their statements as reasons to verify, not as a description of every policy. The text of your own policy controls.
Questions to ask before you prescribe peptides
- Does my policy cover peptide and compounded therapy within my scope, and does it exclude unapproved, off-label or compounded substances?
- Do I need to notify you or amend my application before adding peptide services?
- Does coverage depend on sourcing, such as using only licensed 503A or 503B pharmacies?
- Is there an endorsement for peptides, and how does it change the exclusions?
- Does coverage apply in every state where I treat patients, including by telehealth?
- Are licensing board defense costs covered, and at what limit?
- Is the policy claims-made or occurrence, and what tail coverage applies if I change carriers?
Get the answers in writing, ideally as an endorsement, not an email.
Work with an agency that places malpractice coverage for medical professionals
E&Y Insurance Agency in Bloomfield Hills, Michigan is highly experienced in placing malpractice insurance for medical professionals. We review your current policy, flag exclusions that could affect peptide services, and help you get coverage terms confirmed in writing before a claim, not after one.
Contact E&Y Insurance Agency in Bloomfield Hills for a malpractice coverage review: 248 362 1313
Frequently asked questions
Does malpractice insurance cover peptide therapy? Rarely. Many policies exclude unapproved, off-label or compounded drugs, so confirm in writing.
Are peptides FDA-approved? Most peptides used in wellness and regenerative clinics are not. An FDA advisory vote in July 2026 is not an approval.
Can nurse practitioners and physician assistants prescribe peptides? It depends on state scope of practice and any required physician agreement, and your coverage must match it.
This article is general information, not legal or insurance advice. Coverage depends on the exact wording of each policy. Regulatory status is as of November 1, 2026.
